Merck & Co. (MRK) Stake Increased by Brick & Kyle Associates
Brick & Kyle Associates boosted its position in Merck & Co. (NYSE:MRK) by 1.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 42,113 shares of the company’s stock after buying an additional 787 shares during the period. Merck & Co. comprises about 2.0% of Brick & Kyle Associates’ holdings, making the stock its 13th largest position. Brick & Kyle Associates’ holdings in Merck & Co. were worth $2,426,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently modified their holdings of the company. Americafirst Capital Management LLC bought a new position in Merck & Co. during the second quarter valued at approximately $115,000. NewSquare Capital LLC increased its position in Merck & Co. by 14.2% in the second quarter. NewSquare Capital LLC now owns 2,104 shares of the company’s stock valued at $121,000 after buying an additional 261 shares in the last quarter. First New York Securities LLC NY bought a new position in Merck & Co. during the second quarter valued at approximately $121,000. Lowe fs LLC increased its position in Merck & Co. by 1.8% in the second quarter. Lowe fs LLC now owns 2,619 shares of the company’s stock valued at $151,000 after buying an additional 46 shares in the last quarter. Finally, JNBA Financial Advisors increased its position in Merck & Co. by 3.1% in the second quarter. JNBA Financial Advisors now owns 3,012 shares of the company’s stock valued at $174,000 after buying an additional 91 shares in the last quarter. Institutional investors and hedge funds own 72.93% of the company’s stock.
Merck & Co. (NYSE:MRK) traded up 0.81% on Friday, hitting $62.41. The stock had a trading volume of 13,605,282 shares. Merck & Co. has a 1-year low of $47.97 and a 1-year high of $64.00. The stock has a market capitalization of $172.58 billion, a price-to-earnings ratio of 34.23 and a beta of 0.63. The company has a 50-day moving average price of $62.76 and a 200-day moving average price of $58.03.
Merck & Co. (NYSE:MRK) last announced its quarterly earnings data on Friday, July 29th. The company reported $0.93 earnings per share for the quarter, topping the consensus estimate of $0.91 by $0.02. Merck & Co. had a return on equity of 23.41% and a net margin of 13.01%. The company earned $9.84 billion during the quarter, compared to analyst estimates of $9.79 billion. During the same quarter last year, the firm posted $0.86 EPS. The firm’s revenue for the quarter was up .6% on a year-over-year basis. Equities analysts predict that Merck & Co. will post $3.75 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, October 7th. Shareholders of record on Thursday, September 15th will be issued a dividend of $0.46 per share. This represents a $1.84 dividend on an annualized basis and a yield of 2.95%. The ex-dividend date of this dividend is Tuesday, September 13th. Merck & Co.’s payout ratio is presently 101.10%.
MRK has been the topic of several research reports. Goldman Sachs Group Inc. reiterated a “neutral” rating and issued a $60.00 price objective on shares of Merck & Co. in a report on Wednesday, June 8th. Citigroup Inc. reiterated a “neutral” rating and issued a $65.00 price objective on shares of Merck & Co. in a report on Wednesday, August 10th. BMO Capital Markets upgraded shares of Merck & Co. from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $62.00 to $72.00 in a report on Friday, August 5th. Jefferies Group decreased their price objective on shares of Merck & Co. from $54.00 to $53.00 and set a “hold” rating on the stock in a report on Tuesday, June 14th. Finally, Morgan Stanley set a $60.00 target price on shares of Merck & Co. and gave the company a “hold” rating in a research report on Tuesday, September 13th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating and nine have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of €63.20 ($70.23).
In other Merck & Co. news, insider Weir Mirian M. Graddick sold 45,000 shares of Merck & Co. stock in a transaction dated Tuesday, July 5th. The stock was sold at an average price of €57.99 ($64.43), for a total transaction of €2,609,550.00 ($2,899,500.00). Following the completion of the transaction, the insider now owns 123,151 shares of the company’s stock, valued at approximately €7,141,526.49 ($7,935,029.43). The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Clark Golestani sold 3,000 shares of Merck & Co. stock in a transaction dated Wednesday, August 10th. The shares were sold at an average price of €63.03 ($70.03), for a total value of €189,090.00 ($210,100.00). The disclosure for this sale can be found here. Company insiders own 0.05% of the company’s stock.
Merck & Co. Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.